BE of parenterals [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2018-10-08 11:53  – Posting: # 19416
Views: 1,416

Hi Varsha,

» As per guideline we need not to perform any Bioequivalence studies for Injectables.

It’s not that simple. See e.g., the EMA’s GL page 23.

» But Enoxaparin sodium being a biologically derived product, is there any need of performing the BA-BE studies.

That’s not the point. See the FDA’s guidance for conditions whether the in vivo PD (!) study can be waived.

» Does the guideline differs for a biologically derived product?

Differ to what? To get an idea, see the EMA’s guidelines on biosimilars.

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,688 posts in 4,178 threads, 1,352 registered users;
online 9 (0 registered, 9 guests [including 7 identified bots]).
Forum time (Europe/Vienna): 18:16 CEST

An expert is one who knows more and more
about less and less.    Nicholas Murray Butler

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5